-
An investigation of the efficacy of polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom.
Bradley, A.; Journal of Dairy Sci., Jan 2015.
Analysis of milk production data after the use of a commercially available vaccine against mastitis, demonstrated a return on investment of 2.6 to 1 based on milk yield alone.
-
Observation of mastitis parameters in three herds before and during the first 12 months of a vaccination program.
Biggs, A.; NMC, 2014.
Clinical mastitis reduced by 54%, S. aureus reduced by 71% and first infections reduced by 49%.
-
Mastitis control: the use of a vaccine.
Torres, E.; NMC, 2014.
Evaluate the effectiveness of two different vaccination protocols against bovine mastitis during lactation (STARTVAC®, HIPRA).
-
Control of mastitis and Somatic Cell Count in Mediterranean buffaloes using STARTVAC® vaccine: comparison of two clinical trials.
Guccine, J.; NMC, 2014.
Two different clinical trials based on STARTVAC® vaccine use were evaluated for the first time in dairy Mediterranean Buffalo.
-
Case study of a novel approach to mastitis vaccination in two dairy herds in the United Kingdom.
Drysdale, R.; NMC, 2014.
A simplified vaccination protocol proved effective in reducing severity and case rate of coliform mastitis.
-
Preliminary observation of mastitis parameters in 3 herds before and during the first 12 monthsof a rolling 3 months vaccination program with STARTVAC®.
Biggs, A.; BMC 2013.
Reduction of clinical mastitis, S. aureus prevalence and first infections, Increase of the percentage of healthy animals. -
Case study, controlling clinical mastitis in a dairy herd using a multivalent vaccine.
May, T. W.; NMC 2013.
Increase of animals with SCC < 200.000, decrease of clinical mastitis rate, incidence of mastitis must be reduced by 10 cases per 100 cows per year in order to cover the costs of vaccination. -
Case study, practical aproach for lowering the incidence of mastitis and the use of antibiotics on a dairy farm in Flanders.
Tacken, G.; NMC 2013.
Results were much less cases of acute severe mastitis, SCC reduction, culling rate reduction and reduction of mortalility, reduction in milk losses and treatment costs. -
The role of vaccination in Coliform mastitis control.
Bradley, A.; U. Ghent 2013.
Increase of milk production, decrease of mastitis severity (no culling for toxic mastitis). -
Case study, controlling Staphylococcus aureus in a flemish herd.
Coomans, D.; NMC 2013.
Increase of animals with SCC < 200,000, decrease of clinical mastitis rate, decrease of culling rate, reduction of the cost of mastitis antibiotics and increase of milk production per cow per year. -
Case study, a milk quality programme in a UK dairy herd.
Drysdale, R.; NMC 2013.
Reduction of BTSCC, reduction of culling rate, reduction of clinical mastitis, increase of healthy animals < 200.000 cells/ml. -
Field study, use of the STARTVAC® vaccine under practical conditions on a dairy farm in northern Germany.
Tischer, M.; WBC 2012.
Reduction in the incidence of clinical mastitis from 6,3% to 4,3%, reduction in the individual SCC from 382.000 to 269.000, new infection rate decrease (8% in heifers and 13% in cows) and also the new infection rate during the dryoff. -
Results of one year protocol with STARTVAC® mastitis vaccine, case study.
Sousa, J.; WBC 2012.
Reduction in BTSCC, S. aureus prevalence 19%to 3%, less systemic antibiotic treatments 24 to 10, less clinical mastitis cases 92 to 77. -
Mastitis vaccination as a tool to improve milk quality, field study in a portuguese dairy farm.
Jimenez, L. M.; WBC 2012.
Redution of E. coli infections in 17%, reduction of clinical mastitis in 65% ,reduction of new infection rate 8,8% vs 11,8% and clearance of S. aureus isolates in vaccinated vs 3% in non vaccinated. -
Economic impact of STARTVAC® use in a portuguese dairy herd.
Gonçalves, E. P.; WBC 2012.
Improvement in BTSCC, reduction in number of infected quarters and animals deaths and increase in net profit. -
Epidemiological and clinical evaluation of STARTVAC® vaccine in Staphylococcus aureus infected dairy herds.
Pinho, L.; WBC 2012.
Decrease of S. aureus prevalence, lower BTSCC, and individual SCC. -
Effect of the STARTVAC® vaccination in controlling intrammamary infection caused by Staphylococcus aureus.
Wernitznig, M. J.; WBC 2012.
Increase the number of animals SCC < 100.000, reduce the number of animals with S. aureus infection and decrease BTCC. -
Bulk tank somatic cell count and staphilococcus aureus control through management improvement in an italian dairy herd.
Geninatti, G.; WBC 2012.
Reduction in BTSCC 650.000 to 250.000, clearance of S. aureus isolates after vaccination. -
Use of a vaccine to prevent subclinical mastitis caused by Staphylococcus aureus, field experience.
Wernitznig, M. J.; EBF 2011.
No new infections caused by S. auerus after vaccination, healthy cows SCC < 100.000 increased in 45%, heifers free of mastitis. -
STARTVAC® vaccination field trial in the northen region of Spain.
Ortega, R.; EBF 2011.
Less clinical mastitis 20% to 5%, reduction of mastitis causing pathogens prevalence E. coli 33,35 to 7,8%, S. aureus 11,7% to 2%, reduction of SCC 600.000 to 283.000 and increase of healthy cows 45% to 60%. -
Field experience with a bovine mastitis vaccine in the north-east of Spain.
Franquesa, O.; EBF 2011.
Decrease in SCC 330.000 to 305.000, increase of healthy cows from 55% to 64%, decrease of new infection rate from 26,4% to 19,8% and decrease of clinical mastitis rate 91,8% vs 67%. -
Coliform mastitis herd control program field experience.
Sesto, F.; EBF 2011.
BTSCC decrease from 246.000 to 210.000, more healthy cows, less chronic cows with SCC >1.000.000 cels/ml. -
Report on multifocal essays for the development of the STARTVAC® vaccine acording to a new protocol.
Schmitt. E., SNGTV 2011.
Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000. -
Report on multifocal essays for the development of the STARTVAC® vaccine acording to a new protocol.
Schmitt. E., STARTVAC Library 2011.
Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000.
